시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
헤모크로마토시스(철과잉증) 치료 시장 보고서(2025년)
Hemochromatosis (Iron Overload) Disease Treatment Global Market Report 2025
상품코드 : 1825405
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

헤모크로마토시스(철과잉증) 치료 시장 규모는 향후 수년간 안정된 성장이 전망됩니다. 2029년에는 CAGR 3.7%로 331억 2,000만 달러로 성장합니다. 예측 기간의 성장은 맞춤형 의료 접근법, 치료 혁신의 발전, 스크리닝 및 인식 개선 프로그램 증가, 유전자 연구에서의 공동 연구, 세계 건강 구상에 기인하는 것으로 보입니다. 예측 기간 중 세계 주요 동향으로는 환자 교육 및 인식 제고, 유전자 치료 및 분자 치료의 탐구, 원격의료 및 원격 모니터링 서비스, 디지털 헬스 플랫폼의 통합, 치료 접근성의 전 세계적 확대 등이 있습니다.

향후 5년간 3.7%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 프랑스와 영국에서 수입되는 치료용 정맥주사 시스템 및 철분 킬레이트제에 대한 접근을 제한하고, 장기 손상을 악화시키며, 대사이상 치료 비용을 증가시킬 수 있으므로 큰 도전이 될 수 있습니다. 또한 상호 관세와 무역 긴장의 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

빈혈 유병률 증가는 혈색소침착장애(철분 과다증) 치료제 시장의 성장을 가속할 것으로 예측됩니다. 빈혈은 적혈구(RBC) 수 감소와 헤모글로빈 농도 감소를 특징으로 하는 혈액 질환으로, 신체 기관과 조직에 산소 공급량 감소로 이어집니다. 혈색소침착장애(철분 과다증) 질환의 치료는 철분 킬레이트제를 사용하여 빈혈을 예방하고, 장기 손상을 피하고, 혈액 질환과 관련된 합병증을 관리하는 데 도움을 주는 것을 목표로 합니다. 예를 들어 스위스에 본부를 둔 세계보건기구(WHO)는 2023년 12월 전 세계 6-59개월 아동의 40%, 임산부의 37%, 15-49세 여성의 30%가 빈혈을 앓고 있는 것으로 추정하고 있습니다. 그 결과, 빈혈 유병률 증가는 혈색소침착장애(철분 과다증) 질환 치료제 시장을 발전시킬 것으로 예측됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Hemochromatosis is a genetic disorder marked by the excessive absorption and storage of iron throughout the body, affecting organs such as the liver, heart, pancreas, and joints and potentially leading to severe health complications. The primary goal of treatment is to manage iron levels and prevent associated complications, emphasizing early detection of the disease.

Two main types of hemochromatosis exist such as hereditary hemochromatosis and acquired hemochromatosis. Hereditary hemochromatosis (HH) is a genetic disorder characterized by the abnormal absorption and accumulation of iron. Various treatments, including therapeutic phlebotomy and iron chelation therapy, are employed to manage this condition. These treatments are utilized by different end-users such as hospitals and surgical centers in the effort to address and mitigate the effects of excessive iron accumulation in the body.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hemochromatosis (iron overload) disease treatment market research report is one of a series of new reports from The Business Research Company that provides hemochromatosis (iron overload) disease treatment market statistics, including hemochromatosis (iron overload) disease treatment industry global market size, regional shares, competitors with hemochromatosis (iron overload) disease treatment market share, detailed hemochromatosis (iron overload) disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hemochromatosis (iron overload) disease treatment industry. This hemochromatosis (iron overload) disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemochromatosis (iron overload) disease treatment market size has grown steadily in recent years. It will grow from $27.91 billion in 2024 to $28.62 billion in 2025 at a compound annual growth rate (CAGR) of 2.6%. The growth in the historic period can be attributed to clinical awareness and diagnosis, therapeutic advancements, genetic screening and early detection, prevalence of hereditary hemochromatosis, research and clinical trials.

The hemochromatosis (iron overload) disease treatment market size is expected to see steady growth in the next few years. It will grow to $33.12 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to personalized medicine approaches, advancements in therapeutic innovation, increased screening and awareness programs, collaboration in genetic research, global health initiatives. Major trends in the forecast period include focus on patient education and awareness, exploration of genetic and molecular therapies, telemedicine and remote monitoring services, integration of digital health platforms, global expansion of treatment accessibility.

The forecast of 3.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge by restricting access to therapeutic phlebotomy systems and iron chelation drugs imported from France and the UK, potentially worsening organ damage and increasing metabolic disorder treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of anemia is anticipated to drive growth in the hemochromatosis (iron overload) disease treatment market. Anemia is a blood disorder characterized by a reduced number of red blood cells (RBCs) or lower hemoglobin levels, leading to decreased oxygen delivery to the body's organs and tissues. Treatment for hemochromatosis (iron overload) disease aims to prevent anemia by using iron chelator medications, which help avoid organ damage and manage complications linked to blood disorders. For example, in December 2023, the World Health Organization (WHO), a Switzerland-based agency, estimated that 40% of children aged 6 to 59 months, 37% of pregnant women, and 30% of women aged 15 to 49 worldwide are affected by anemia. Consequently, the increasing prevalence of anemia is expected to propel the hemochromatosis (iron overload) disease treatment market forward.

The increasingly stressful lifestyle prevalent today is expected to significantly contribute to the growth of the hemochromatosis (iron overload) disease treatment market. Stressful lifestyles exert profound effects on both physical and mental health, with prolonged exposure to high stress levels potentially leading to various health conditions, including hemochromatosis (iron overload) disease. Treatment for this condition, characterized by excessive iron accumulation in the body, not only addresses the physical aspects of the disease but also plays a pivotal role in alleviating the emotional and psychological stress often associated with managing a chronic health condition. For instance, data from the American Psychiatric Association in December 2022 revealed that over one in four Americans (26%) anticipated experiencing increased stress levels at the commencement of 2023, a rise from one in five (20%) reported in the previous year. This escalation in stressful lifestyles acts as a driving force propelling the hemochromatosis (iron overload) disease treatment market.

Leading companies in the hemochromatosis (iron overload) disease treatment market are securing approvals for drugs like deferiprone, designed for patients with transfusional iron overload to help reduce iron levels in the body and prevent complications like organ damage. Deferiprone is a medication used to treat iron overload in individuals who have undergone frequent blood transfusions, a common scenario in conditions like thalassemia, sickle cell anemia, and other chronic anemias. For instance, in March 2023, Chiesi Global Rare Diseases Inc., a U.S.-based business unit, announced the approval of FERRIPROX MR (deferiprone) extended-release tablets in Canada. FERRIPROX MR is indicated for the treatment of transfusional iron overload in patients with thalassemia syndromes when existing chelation therapy is insufficient, including patients with sickle cell disease (SCD) or other anemias. Deferiprone is an orally active iron-chelating agent that reduces iron concentration by penetrating cell membranes, binding excess iron, and facilitating its removal from organs and tissues.

In August 2022, CSL Limited, an Australian biotechnology company specializing in drug manufacturing for hemochromatosis (iron overload) disease, completed the acquisition of Vifor Pharma for an undisclosed sum. This strategic acquisition is set to reinforce CSL's dedication to patient care by providing state-of-the-art medications and extending its presence in the realms of nephrology and iron deficiency treatments. Vifor Pharma, based in Switzerland, is a pharmaceutical company renowned for its expertise in offering treatments designed specifically for hemochromatosis (iron overload) disease.

Major companies operating in the hemochromatosis (iron overload) disease treatment market report are Pfizer Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Abbott Laboratories, Merck KGaA, Laboratory Corporation, Quest Diagnostics, Chiesi Farmaceutici S.p.A., Apotex Inc., Shire PLC, CSL Vifor, ARUP Laboratories, Myriad Genetics Inc., Fulgent Genetics, Ionis Pharmaceuticals Inc., Invitae Corp., Abcam plc., GeneDx, Ambry Genetics, La Jolla Pharmaceutical Company, Silence Therapeutics, PreventionGenetics, DisperSol Technologies LLC., Hinoman Ltd.

North America was the largest region in the hemochromatosis (Iron Overload) disease treatment market in 2024. The regions covered in the hemochromatosis (iron overload) disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hemochromatosis (iron overload) disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemochromatosis (iron overload) disease treatment market consists of revenues earned by entities by providing genetic testing services, transplantation services, and blood testing and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemochromatosis (iron overload) disease treatment market also consists of sales of vitamin C supplements, blood pressure drugs, and iron-free supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemochromatosis (Iron Overload) Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemochromatosis (iron overload) disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hemochromatosis (iron overload) disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemochromatosis (iron overload) disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hemochromatosis (Iron Overload) Disease Treatment Market Characteristics

3. Hemochromatosis (Iron Overload) Disease Treatment Market Trends And Strategies

4. Hemochromatosis (Iron Overload) Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hemochromatosis (Iron Overload) Disease Treatment Growth Analysis And Strategic Analysis Framework

6. Hemochromatosis (Iron Overload) Disease Treatment Market Segmentation

7. Hemochromatosis (Iron Overload) Disease Treatment Market Regional And Country Analysis

8. Asia-Pacific Hemochromatosis (Iron Overload) Disease Treatment Market

9. China Hemochromatosis (Iron Overload) Disease Treatment Market

10. India Hemochromatosis (Iron Overload) Disease Treatment Market

11. Japan Hemochromatosis (Iron Overload) Disease Treatment Market

12. Australia Hemochromatosis (Iron Overload) Disease Treatment Market

13. Indonesia Hemochromatosis (Iron Overload) Disease Treatment Market

14. South Korea Hemochromatosis (Iron Overload) Disease Treatment Market

15. Western Europe Hemochromatosis (Iron Overload) Disease Treatment Market

16. UK Hemochromatosis (Iron Overload) Disease Treatment Market

17. Germany Hemochromatosis (Iron Overload) Disease Treatment Market

18. France Hemochromatosis (Iron Overload) Disease Treatment Market

19. Italy Hemochromatosis (Iron Overload) Disease Treatment Market

20. Spain Hemochromatosis (Iron Overload) Disease Treatment Market

21. Eastern Europe Hemochromatosis (Iron Overload) Disease Treatment Market

22. Russia Hemochromatosis (Iron Overload) Disease Treatment Market

23. North America Hemochromatosis (Iron Overload) Disease Treatment Market

24. USA Hemochromatosis (Iron Overload) Disease Treatment Market

25. Canada Hemochromatosis (Iron Overload) Disease Treatment Market

26. South America Hemochromatosis (Iron Overload) Disease Treatment Market

27. Brazil Hemochromatosis (Iron Overload) Disease Treatment Market

28. Middle East Hemochromatosis (Iron Overload) Disease Treatment Market

29. Africa Hemochromatosis (Iron Overload) Disease Treatment Market

30. Hemochromatosis (Iron Overload) Disease Treatment Market Competitive Landscape And Company Profiles

31. Hemochromatosis (Iron Overload) Disease Treatment Market Other Major And Innovative Companies

32. Global Hemochromatosis (Iron Overload) Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemochromatosis (Iron Overload) Disease Treatment Market

34. Recent Developments In The Hemochromatosis (Iron Overload) Disease Treatment Market

35. Hemochromatosis (Iron Overload) Disease Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기